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 EDITORIAL 
 Small cell lung cancer (SCLC) accounts for about 15% – 20% of 
lung cancers, and two-thirds of SCLCs are diagnosed as extensive 
disease . SCLC is very sensitive to chemotherapy, with initial 
response rates varying between 70% and 85%. Current standard 
chemotherapy consists of a combination of a platinum compound 
with etoposide. Thoracic radiotherapy is recommended in lim-
ited disease, as well as prophylactic cranial irradiation in 
 chemotherapy-responding patients, allowing a modest gain in 
overall survival. However, the vast majority of patients rapidly 
relapse, develop resistance to therapy, and present an aggressive 
clinical course . No major therapeutic progress has been achieved 
in SCLC in the past decade and prognosis remains dismal, with 
about 11% and 2% survival at 5 years in limited disease and exten-
sive disease, respectively ( 1 ). 
 Anti-angiogenic therapy is emerging as a new approach in 
cancer treatment. Bevacizumab, an anti – vascular endothelial growth 
factor (VEGF) monoclonal antibody, provides  progression-free 
survival beneﬁ ts when combined with interferon alpha in meta-
static renal cancer and in combination with chemotherapy in 
advanced breast cancer, as well as a survival beneﬁ t in colorectal 
and non – small cell lung cancers, in combination with chemother-
apy. VEGF receptor tyrosine kinase inhibitors also prolong sur-
vival in renal and hepatic carcinoma ( 2 ). Tumor angiogenesis is 
expected to play a role in SCLC because VEGF is expressed in 
approximately 80% of the cancers ( 3 ). 
 In this issue of the Journal, Lee et al. ( 4 ) reported the results of a 
randomized, double-blind, placebo-controlled trial in SCLC com-
bining thalidomide, a drug with bona ﬁ de anti-angiogenic activity, 
with carboplatin and etoposide chemotherapy. The study is sound 
and the results are without appeal — thalidomide combined with 
chemotherapy does not extend progression-free or overall survival 
compared with chemotherapy alone. Worse decreased survival of 
patients with extensive disease, and increased risk of thrombotic 
events were observed in thalidomide-treated patients. 
 In 2008, Pujol et al. ( 5 ) already reported a phase III study in 
which thalidomide was added to etoposide, cisplatin, cyclophosph-
amide, and 4-epidoxorubicin – based chemotherapy to extensive dis-
ease patients who initially responded to two cycles of chemotherapy. 
No survival beneﬁ t compared with chemotherapy alone was 
observed. Previously, two small phase II studies testing thalidomide 
with carboplatin – etoposide followed by a thalidomide maintenance 
in patients with extensive disease suggested evidence for activity 
( 6 , 7 ), and another phase II study, using an irinotecan – carboplatin 
regimen, did not ( 8 ). Treatment-related side effects (including neu-
ropathy, emesis, constipation, drowsiness, neutropenia, thrombotic 
events) led to thalidomide discontinuation in several patients 
included in these trials ( 5 , 8 ). Nowadays, the phase III  studies by 
Pujol et al. and Lee et al. deﬁ nitely close the door to using thalido-
mide in SCLC ( 9 ). These negative studies, however, must not be 
disregarded. Rather they should provoke a discussion on why thali-
domide failed in SCLC and where to go from there. 
 Two simple explanations addressing these failures can be advanced 
at this time to launch the discussion. Either something is wrong with 
thalidomide itself or SCLC could be the wrong cancer to test it. 
 To the ﬁ rst explanation: Thalidomide might not be an effective 
anti-angiogenic drug as initially assumed. Although thalidomide 
was shown to suppress angiogenesis 15 years ago, the responsible 
mechanism has remained largely elusive ( 10 , 11 ). Its main biologi-
cal activities appear to be inhibition of inﬂ ammation (eg, suppres-
sion of nuclear factor kappa-B, cyclooxygenase-2, tumor necrosis 
factor, interleukin-1 and -6) and immunomodulation (eg, stimula-
tion of T-cell activity and T helper cell 1 differentiation) ( 11 ). In 
humans, although thalidomide was reported to modulate the 
expression of angiogenic molecules ( 12 ), there is no direct evi-
dence that its therapeutic efﬁ cacy in multiple myeloma and ery-
thema nodosum leprae (the two indications for which thalidomide 
has been recently registered after its withdrawal in the 1960s 
because of its teratogenicity) is due to the inhibition of angiogen-
esis ( 13 ). Considering the role of myeloid and inﬂ ammatory cells 
in promoting angiogenesis ( 14 ), one could contemplate the possi-
bility that the supposed anti-angiogenic effect of thalidomide is 
secondary to its anti-inﬂ ammatory activity and thus be context 
dependent. Because SCLC is poorly inﬁ ltrated with inﬂ ammatory 
and immune cells, thalidomide may simply miss the target. 
Unfortunately, from these studies, we will not know whether tha-
lidomide modiﬁ ed angiogenesis in treated patients. This condition 
reminds us that we deeply need validated biomarkers of angiogen-
esis to monitor anti- angiogenic effects in patients ( 15 ). 
 To the second explanation: SCLC might be the wrong disease 
to test thalidomide and possibly other anti-angiogenic drugs. 
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Clearly, not every tumor is equally angiogenic or equally depen-
dent on angiogenesis. The extreme example is renal cancer, which 
presents a strong activation of the VEGF pathway, is highly angio-
genic, strongly depends on angiogenesis, and responds well to the 
VEGF inhibitor bevacizumab and to the VEGF receptor tyrosine 
kinase inhibitors sorafenib and sunitinib ( 16 ). By contrast, some 
tumors may grow by using preexisting vessels (vascular co-option) 
or by forming vessels through intussusception ( 17 ). Furthermore, 
tumors can rapidly adapt to inhibition of angiogenesis and develop 
resistance ( 18 ). Unfortunately, at this point, we still know little 
about the vascular biology of SCLC, its dependence on angiogen-
esis, and its mechanisms of adaptation to anti-angiogenesis to 
predict whether SCLC is possibly sensitive to angiogenesis 
inhibition. 
 Where do we go from there? Concerning thalidomide, the 
notion that this drug has clinically signiﬁ cant anti-angiogenic 
activity should be revisited. In future studies, if any, it will be 
important to collect direct evidence for anti-angiogenic effects in 
treated patients by using biomarkers of angiogenesis, in particular 
imaging-based approaches ( 15 ). Furthermore, in view of its anti-
inﬂ ammatory and immunomodulatory effects, and the angiogenesis-
promoting effects of inﬂ ammation, solid cancers with a strong 
inﬂ ammatory component, such as melanoma and colorectal, liver, 
prostate, and some breast cancers, should be preferred ( 19 ). 
Concerning anti-angiogenesis in SCLC, before any new anti-
angiogenic therapy is tested, it is reasonable to await the outcome 
of the 13 ongoing trials investigating bevacizumab in various com-
binations. Two bevacizumab-based phase II trials were reported in 
2007, one of them suggesting a potential improvement of progression-
free survival, with acceptable toxicity, however not compelling 
enough to progress to a phase III trial ( 20 , 21 ). A randomized phase 
II trial using the VEGF receptor tyrosine kinase inhibitor vande-
tanib in maintenance therapy after standard chemotherapy and 
radiotherapy in limited disease and extensive disease could not 
demonstrate any progression-free or overall survival beneﬁ t ( 21 ). 
 In conclusion, developing novel anti-angiogenic drugs and 
therapies remains a major challenge in clinical oncology, and in 
this regard, SCLC is a particularly difﬁ cult case because its biology 
is still not fully characterized. Insufﬁ cient knowledge of its biology 
may have also contributed to the systematic failure of targeted 
therapy approaches attempted ( 22 ). Rather than running from 
failure to failure, it may be more reasonable to go back to experi-
mental work, including the development and analysis of transgenic 
SCLC models ( 23 ), to better understand SCLC biology and iden-
tify robust therapeutic targets. Concerning phase I and II trials 
with anti-angiogenic compounds, the measurement of functional, 
cellular, or molecular parameters of angiogenesis may provide 
evidence on drug activity and tumor – host response that clinicians 
can use to determine whether or not move on to large and costly 
phase III trials ( 15 ). 
 References 
  1.  Navada  S ,   Lai  P ,  Schwartz  AG ,  Kalemkerian  GP .  Temporal trends in small 
cell lung cancer: analysis of the national Surveillance, Epidemiology, and 
End-Results (SEER) database .  J Clin Oncol .  2006 ; 24 ( 18S ).  Abstract 7082 . 
  2.  Kerbel  RS .  Tumor angiogenesis .  N Engl J Med .  2008 ; 358 ( 19 ): 
 2039 – 2049 . 
  3.  Dowell  JE ,  Amirkhan  RH ,  Lai  WS ,  et al .  Survival in small cell lung cancer 
is independent of tumor expression of VEGF and COX-2 .  Anticancer Res . 
 2004 ; 24 ( 4 ): 2367 – 2373 . 
  4.  Lee  SM ,  Woll  PJ ,  Rudd  R , et al .  Anti-angiogenic therapy using thalido-
mide combined with chemotherapy in small cell lung cancer: a random-
ized double-blind placebo-controlled trial .  J Natl Cancer Inst . 
 2009 ; 101 ( 15 ): 1049 – 1057 . 
  5.  Pujol  JL ,  Breton  JL ,  Gervais  R , et al .  Phase III double-blind, placebo-
controlled study of thalidomide in extensive-disease small-cell lung cancer 
after response to chemotherapy: an intergroup study FNCLCC cleo04 
IFCT 00-01 .  J Clin Oncol .  2007 ; 25 ( 25 ): 3945 – 3951 . 
  6.  Lee  SM ,  James  L ,  Buchler  T ,  Snee  M ,  Ellis  P ,  Hackshaw  A .  Phase II trial 
of thalidomide with chemotherapy and as maintenance therapy for 
patients with poor prognosis small-cell lung cancer .  Lung Cancer . 
 2008 ; 59 ( 3 ): 364 – 368 . 
  7.  Dowlati  A ,  Subbiah  S ,  Cooney  M , et al .  Phase II trial of thalidomide as 
maintenance therapy for extensive stage small cell lung cancer after 
response to chemotherapy .  Lung Cancer .  2007 ; 56 ( 3 ): 377 – 381 . 
  8.  Riedel  RF ,  Crawford  J ,  Dunphy  F ,  Herndon  JE  II ,  Garst  J ,  Kelley  MJ . 
 Phase II study of carboplatin, irinotecan, and thalidomide combination in 
patients with extensive stage small-cell lung cancer .  Lung Cancer . 
 2006 ; 54 ( 3 ): 431 – 432 . 
  9.  Rossi  A ,  Gridelli  C ,  Bria  E .  Thalidomide in small-cell lung cancer: is it a 
tombstone? .  J Clin Oncol .  2008 ; 26 ( 1 ): 160 .  Author reply 160 . 
  10.  D’Amato  RJ ,  Loughnan  MS ,  Flynn  E ,  Folkman  J .  Thalidomide is an 
inhibitor of angiogenesis .  Proc Natl Acad Sci U S A .  1994 ; 91 ( 9 ): 
 4082 – 4085 . 
  11.  Paravar  T ,  Lee  DJ .  Thalidomide: mechanisms of action .  Int Rev Immunol . 
 2008 ; 27 ( 3 ): 111 – 135 . 
  12.  Vacca  A ,  Scavelli  C ,  Montefusco  V , et al .  Thalidomide downregulates 
angiogenic genes in bone marrow endothelial cells of patients with active 
multiple myeloma .  J Clin Oncol .  2005 ; 23 ( 23 ): 5334 – 5346 . 
  13.  Ribatti  D ,  Vacca  A .  Is thalidomide a true anti-angiogenic molecule in 
multiple myeloma?  Haematologica .  2002 ; 87 ( 4 ): 344 – 345 . 
  14.  Shojaei  F ,  Zhong  C ,  Wu  X ,  Yu  L ,  Ferrara  N .  Role of myeloid cells in 
tumor angiogenesis and growth .  Trends Cell Biol.  2008 ; 18 ( 8 ): 372 – 378 . 
  15.  Sessa  C ,  Guibal  A ,  Del Conte  G ,  Ruegg  C .  Biomarkers of angiogenesis for 
the development of antiangiogenic therapies in oncology: tools or decora-
tions?  Nat Clin Pract Oncol .  2008 ; 5 ( 7 ): 378 – 391 . 
  16.  Rini  BI .  Vascular endothelial growth factor-targeted therapy in renal cell 
carcinoma: current status and future directions .  Clin Cancer Res. 
 2007 ; 13 ( 4 ): 1098 – 1106 . 
  17.  Carmeliet  P ,  Jain  RK .  Angiogenesis in cancer and other diseases .  Nature . 
 2000 ; 407 ( 6801 ): 249 – 257 . 
  18.  Bergers  G ,  Hanahan  D .  Modes of resistance to anti-angiogenic therapy . 
 Nat Rev Cancer .  2008 ; 8 ( 8 ): 592 – 603 . 
  19.  Mantovani  A ,  Allavena  P ,  Sica  A ,  Balkwill  F .  Cancer-related inﬂ ammation . 
 Nature .  2008 ; 454 ( 7203 ): 436 – 444 . 
  20.  Sandler  A ,  Szwaric  S ,  Dowlati  A ,  Moore  DF Jr ,  Schiller  JH .  A phase II 
study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previ-
ously untreated extensive stage small cell lung cancer (SCLC) (E3501): a 
trial of the Eastern Cooperative Oncology Group .  J Clin Oncol .  2007 ; 25(18S) . 
 Abstract 7564 . 
  21.  Ready  N ,  Dudek  AZ ,  Wang  XF ,  Graziano  S ,  Green  MR ,  Vokes  EE . 
 CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and beva-
cizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC) . 
 J Clin Oncol .  2007 ; 25(18S) .  Abstract 7563 . 
  22.  Rossi  A ,  Maione  P ,  Palazzolo  G , et al .  New targeted therapies and small-
cell lung cancer .  Clin Lung Cancer .  2008 ; 9 ( 5 ): 271 – 279 . 
  23.  Meuwissen  R ,  Berns  A .  Mouse models for human lung cancer .  Genes Dev. 
 2005 ; 19 ( 6 ): 643 – 664 . 
 Note 
 C. Rüegg holds stock in Diagnoplex, a company dedicated to discover and opti-
mize combinations of molecular biomarkers to detect cancers at an early stage 
and receives research funds from Novartis to test the effects of bisphosphonate 
(Zoledronate) on tumor angiogenesis. 
